CoChat

Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations

Open access
Coe, Marion A., Lofwall, Michelle R., Walsh, Sharon L. · 2019 · Journal of Addiction Medicine
Cited by 173

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Buprenorphine is an effective treatment for opioid use disorder. As a high-affinity, partial agonist for the mu-opioid receptor, buprenorphine suppresses opioid withdrawal and craving, reduces illicit opioid use, and blocks exogenous opioid effects including respiratory depression. Other pharmacologic benefits of buprenorphine are its superior safety profile compared with full opioid agonists and its long half-life that allows daily or less-than-daily dosing. New and innovative buprenorphine formulations, with pharmacokinetic profiles that differ from the original tablet formulation, continue to be developed. These include higher bioavailability transmucosal tablets and films and also 6-month implantable and monthly injectable products. This growing array of available formulations allows more choices for patients and increased opportunity for clinicians to individualize treatment; thus, it is important for buprenorphine prescribers to understand these differences.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/adm.0000000000000457

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Metadata

Authors
Coe, M. A., Lofwall, M. R., & Walsh, S. L.
Venue
Journal of Addiction Medicine
Published
2019-03
Volume
13
Issue
2
Pages
93-103
ISSN
  • 1932-0620 (ISSN-L)
  • 1935-3227
OpenAlex
W2898561048
Cited by
173
References
7
FWCI
9.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. https://app.cochat.ai/papers/10.1097/adm.0000000000000457
The paper
Coe, M. A., Lofwall, M. R., & Walsh, S. L. (2019). Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000457

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.